End-to-end Diagnostics AliveDx offers MosaiQ end-to-end, automated, high-throughput microarray solutions for clinical laboratories, presenting a direct upsell opportunity to labs seeking scalable, efficient diagnostic workflows and faster turnaround.

Global Expansion Recent partnerships and regulatory activity, including the FDA 510(k) submission for MosaiQ AiPlex Vasculitis and new distribution agreements, indicate growing international adoption and channel expansion ripe for strategic sales partnerships and co-marketing.

New Assay Launches Introduction of LumiQ immunofluorescence assay and MosaiQ AiPlex CTDplus multiplex assay signals a pipeline of innovative, high-value products that can broaden customer use cases and justify expanded purchasing across labs.

Healthcare Alignment AliveDx’s reagent brands Alba and automated platforms align with hospital and blood bank demand for streamlined workflows, enabling cross-sell to existing customers and expansion within inpatient and transfusion medicine segments.

Mid-market Focus With revenue size in the 10–25M range and a mid-sized employee base, AliveDx presents a scalable partner for mid-market labs; pursue tiered pricing, volume commitments, and regional partner programs to accelerate growth.